NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 72 resultados LastUpdate Última actualización 29/09/2020 [14:21:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



previousPage Página2 de 3 nextPage   por página


TELOMERE-CONTROLLING GENE FAMILY DISCOVERED IN MOUSE THYMUS LYMPHOMA CELL IRRADIATED WITH LOW-DOSE RATE LOW-LEVEL RADIATION, AND METHOD FOR DETECTING SAME

NºPublicación: US2020283836A1 10/09/2020

Solicitante:

KOREA HYDRO & NUCLEAR POWER CO [KR]

CN_111148848_A

Resumen de: US2020283836A1

The present invention relates to a method of detecting a telomere-controlling gene family that responds to low-dose-rate low-level radiation, and more particularly to a method of detecting a telomere-controlling gene that is expressed in common or alone by applying low-dose low-level radiation to mouse thymic lymphoma cells and then measuring the expression levels of telomere-controlling genes. By providing the method of detecting the telomere-controlling gene family that responds to low-dose-rate low-level radiation according to the present invention, telomere-controlling genes can be used as low-level-radiation telomere-controlling genes with which the relationship between radiation exposure and carcinogenesis of industrial and medical workers can be evaluated, as low-level-radiation telomere-controlling genes with which cancer progression and the extent of treatment of cancer patients can be evaluated, and also as a low-level telomere-controlling gene recovery indicator with which the causal relationship between radiation and carcinogenesis can be evaluated.

traducir

ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA

NºPublicación: US2020283542A1 10/09/2020

Solicitante:

GENMAB AS [DK]

JP_2020141689_A

Resumen de: US2020283542A1

Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

traducir

ANTIBODY

NºPublicación: US2020283533A1 10/09/2020

Solicitante:

UNIV OSAKA [JP]

JP_2019201641_A

Resumen de: US2020283533A1

Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

traducir

KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE

NºPublicación: US2020283397A1 10/09/2020

Solicitante:

IMAGO BIOSCIENCES INC [US]

US_2018312474_A1

Resumen de: US2020283397A1

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

traducir

AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA

NºPublicación: US2020283417A1 10/09/2020

Solicitante:

UNIV MARYLAND [US]

CA_3039191_A1

Resumen de: US2020283417A1

The invention relates to new amino dimeric naphthoquinone compounds with antileukemic activity. Compounds of the invention demonstrated increased aqueous solubility compared to previously available dimeric naphthoquinones and potent nanomolar inhibition of cell survival in AML cells. Preferred compounds contained an aziridine or a secondary amino alcohol pharmacophore.

traducir

Compositions and methods for treating hematologic cancers targeting the SIRPalpha - CD47 interaction

NºPublicación: AU2020220183A1 10/09/2020

Solicitante:

HOSPITAL FOR SICK CHILDREN [CA]
UNIV HEALTH NETWORK [CA]

AU_2018256470_A1

Resumen de: AU2020220183A1

The invention relates to modulating the SIRPa - CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided 5 methods and uses of SIRPa polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia.

traducir

Combination therapy using belinostat and pralatrexate to treat lymphoma

NºPublicación: AU2020220197A1 10/09/2020

Solicitante:

SPECTRUM PHARMACEUTICALS INC [US]

Resumen de: AU2020220197A1

The present invention relates to compositions and methods for treating lymphoma in a subject in need thereof, said methods comprising administering to the patient in need thereof a therapeutically effective amount of a combination of belinostat and pralatrexate, wherein said therapeutically effective amount results in a synergistic antiproliferative effect on cancer cell growth.

traducir

Methods for treating acute myeloid leukemia and related conditions

NºPublicación: AU2019230013A1 10/09/2020

Solicitante:

GLYCOMIMETICS INC [US]

WO_2019173229_PA

Resumen de: AU2019230013A1

Methods for treating or inhibiting cancer and/or one or more related conditions by administering to a subject in need thereof an effective amount of a compound of Formula (I) a prodrug thereof or a pharmaceutically acceptable salt of any of the foregoing. For example, methods for treating AML, MDS, neutropenia, and/or mucositis comprising administering a pharmaceutical composition comprising a compound of Formula (I) are described.

traducir

Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies

NºPublicación: AU2019218271A1 10/09/2020

Solicitante:

FORTY SEVEN INC [US]

US_2019248915_A1

Resumen de: AU2019218271A1

Disclosed is a regimen to treat a CD20+ cancer, in particular a lymphoma. The regimen involves several cycles of administration of anti-CD20 and anti-CD47 antibodies at appropriate dosage and administration intervals.

traducir

METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS

NºPublicación: WO2020180663A1 10/09/2020

Solicitante:

KURA ONCOLOGY INC [US]

Resumen de: WO2020180663A1

The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma ("PTCL"), lymphoma is angioimmunoblastic T-cell lymphoma (AITL), acute myeloid leukemia (AML), or chronic myelomonocytic leukemia (CMML), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.

traducir

EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF

NºPublicación: WO2020180733A1 10/09/2020

Solicitante:

IOVANCE BIOTHERAPEUTICS INC [US]

Resumen de: WO2020180733A1

Methods of expanding peripheral blood lymphocytes (PBLs) from blood of patients with hematological malignancies, including lymphomas and leukemias, genetic modifications of expanded PBLs to incorporate chimeric antigen receptors, genetically modified T cell receptors, and other genetic modifications, and uses of such expanded and/or modified PBLs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.

traducir

METHOD TO DIAGNOSE A CMMRD

NºPublicación: WO2020178400A1 10/09/2020

Solicitante:

INST NAT SANTE RECH MED [FR]
ASSIST PUBLIQUE HOPITAUX PARIS APHP [FR]
UNIV SORBONNE [FR]

Resumen de: WO2020178400A1

The present invention relates to the diagnostic of CMMRD. In the present work, the inventors aimed to develop a test that could drastically simplify and improve the diagnosis of CMMRD based on DNA sequence analysis of primary blood cells (PBCs) from patients. Using massive parallel sequencing, they explored the possibility that MSI, the main genomic and functional consequence of constitutive MMR-deficiency, was likely to occur in CMMRD PBCs well before any transformation. Thus the present invention relates to a method of diagnosing a CMMRD cancer or a MSI leukemia/lymphoma in a patient in need thereof.

traducir

METHOD OF IDENTIFYING PATIENTS WITH BORTEZOMIB RESISTANT MULTIPLE MYELOMA AND OTHER BLOOD DISEASES

NºPublicación: WO2020178173A1 10/09/2020

Solicitante:

MAX PLANCK GESELLSCHAFT [DE]

EP_3705584_A1

Resumen de: WO2020178173A1

The present application relates to an in vitro method and a diagnostic kit for identifying resistance to bortezomib treatment in a patient in need thereof by detecting a substitution in the amino acid sequence of the polypeptide β5 (PSMB5). The present application also relates to a composition and preferably to a synergistic composition of bortezomib and a further drug suitable for the treatment of a patient suffering from a disease selected from the group comprising multiple myeloma, mantle cell lymphoma, non-Hodgkin's lymphoma TEMPI syndrome, light chain deposition disease (LCDD), IgG4-related disease, and Scleromyxedema.

traducir

METHODS OF DETECTING AND TREATING VENETOCLAX-RESISTANT ACUTE MYELOID LEUKEMIA

NºPublicación: WO2020181219A1 10/09/2020

Solicitante:

UNIV COLORADO REGENTS [US]

Resumen de: WO2020181219A1

The present disclosure relates to methods of identifying AML patients who will be resistant to venetoclax therapy and methods of treating venetoclax-resistant patients with myeloid leukemia cell differentiation protein (MCL-1) inhibitors.

traducir

CAR-T CELLS WITH HUMANIZED CD19 SCFV

NºPublicación: WO2020180551A1 10/09/2020

Solicitante:

PROMAB BIOTECHNOLOGIES INC [US]
FOREVERTEK BIOTECHNOLOGY CO LTD [CN]

Resumen de: WO2020180551A1

The present invention is directed to a humanized CD19 single-chain variable fragment (scFv), comprising the amino acid sequence of SEQ ID NO: 8. The present invention is also directed to a CD19 chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. The humanized anti-CD19 scFv of the present invention exhibits selective and high-affinity binding to CD19. CD19-CAR T cells based on humanized scFv of the present invention are useful to treat patients with B-cell malignancies including leukemia and lymphomas.

traducir

ADULT T-CELL LEUKEMIA-LYMPHOMA DETECTION METHOD

NºPublicación: WO2020179646A1 10/09/2020

Solicitante:

UNIV SAGA [JP]
OHARA PHARMACEUTICAL CO LTD [JP]

Resumen de: WO2020179646A1

An adult T-cell leukemia-lymphoma (ATL) detection method is provided which involves determining the presence or absence in a target biological sample of DNA methylation of at least one gene selected from the group consisting of SERPINB6, NELL2, THEMIS, ZSCAN18, LAIR1, CD7, RNF130, ZIK1, LYPD3, TMEM45B, POMC, FHIT, MDS2, HOOK1, SORCS3, C2orf40, ZNF662, SPG20, ZNF717, LZTFL1, KLHL34 and BCL9, wherein DNA methylation of at least one of the aforementioned genes indicates that the subject has developed or is at risk of developing ATL. By this means, a new detection method of adult T cell leukemia-lymphoma (ATL) is provided.

traducir

TETRAMERIC PROTEIN SCAFFOLDS AS NANO-CARRIERS OF THERAPEUTIC PEPTIDES FOR TREATING CANCER AND OTHER DISEASES

NºPublicación: WO2020181197A1 10/09/2020

Solicitante:

UNIV MARYLAND [US]
LU WUYUAN [US]
MA BOHAN [CN]

Resumen de: WO2020181197A1

A protein-based peptide drug carrier derived from the tetramerization domain of the chimeric oncogenic protein Bcr/Abl of chronic myeloid leukemia. Peptides to be delivered are grafted to the N-terminal helical region of Bcr/Abl tetramer. To facilitate cellular uptake, an Arg-repeating hexapeptide is added to the C-terminal end of the Bcr/Abl protein. The protein-based delivery strategy provides a clinically viable solution to p53-inspired anticancer therapy and is applicable to the development of many other peptide therapeutics to target other intracellular protein-protein interactions responsible for disease initiation and progression.

traducir

SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE

NºPublicación: WO2020181207A1 10/09/2020

Solicitante:

UNIV MICHIGAN REGENTS [US]

Resumen de: WO2020181207A1

This invention is in the field of medicinal chemistry. In particular, the invention relates to small molecule compounds having bicyclic and tetracyclic quinone scaffolds which have antiproliferative activities through, for example, induction of reactive oxygen species. The invention further processes for preparing, and methods for using these compounds to treat cancer (e.g., pancreatic cancer, leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer).

traducir

TREATMENTS AND DIAGNOSTICS FOR CANCERS

NºPublicación: US2020281946A1 10/09/2020

Solicitante:

UNIV WAYNE STATE [US]

US_2018280412_A1

Resumen de: US2020281946A1

Treatments and diagnostics for treatment efficacy against solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin α2 cleavage products or inhibition of DUB activities from a blood sample to monitor treatment efficacy for castration-resistant prostate cancer (CRPC) or multiple myeloma (MM).

traducir

PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF ACUTE MYELOID LEUKEMIA OR METASTATIC BREAST CANCER

NºPublicación: EP3705474A1 09/09/2020

Solicitante:

PELEMED CO LTD [KR]

US_2020270229_A1

Resumen de: EP3705474A1

The present invention relates to a pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer, comprising, as an active ingredient, an indirubin derivative. When the compound of the present invention is used, it can effectively inhibit the activity of FLT3 kinase and can be usefully used to prevent or treat acute myeloid leukemia or metastatic breast cancer.

traducir

METHODS OF TREATING HIGH RISK MULTIPLE MYELOMA

NºPublicación: EP3703749A1 09/09/2020

Solicitante:

JANSSEN BIOTECH INC [US]

CN_111565751_A

Resumen de: WO2019089832A1

Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.

traducir

METHOD OF IDENTIFYING PATIENTS WITH BORTEZOMIB RESISTANT MULTIPLE MYELOMA AND OTHER BLOOD DISEASES

NºPublicación: EP3705584A1 09/09/2020

Solicitante:

MAX-PLANCK-GESELLSCHAFT ZUR F\u00D6RDERUNG DER WSS EV [DE]

WO_2020178173_A1

Resumen de: EP3705584A1

The present application relates to anin vitromethod and a diagnostic kit for identifying resistance to bortezomib treatment in a patient in need thereof by detecting a substitution in the amino acid sequence of the polypeptide β5 (PSMB5). The present application also relates to a composition and preferably to a synergistic composition of bortezomib and a further drug suitable for the treatment of a patient suffering from a disease selected from the group comprising multiple myeloma, mantle cell lymphoma, non-Hodgkin's lymphoma TEMPI syndrome, light chain deposition disease (LCDD), IgG4-related disease, and Scleromyxedema.

traducir

METHOD FOR TREATING A MULTIPLE MYELOMA

NºPublicación: WO2020176610A1 03/09/2020

Solicitante:

PTC THERAPEUTICS INC [US]

Resumen de: WO2020176610A1

One aspect described herein includes a method for treating a multiple myeloma (MM) in a subject in need thereof comprising, administering to the subject an effective amount of a small molecule compound. More particularly, another aspect described herein includes a method for treating a multiple myeloma in a subject in need thereof comprising, administering to the subject an effective amount of the small molecule compound described herein in combination with a chemotherapeutic agent.

traducir

Treatment Method

NºPublicación: US2020277396A1 03/09/2020

Solicitante:

KIRA BIOTECH PTY LTD [AU]

CN_111565749_A

Resumen de: US2020277396A1

The present invention relates to a method of treating lymphoma in a subject, and more particularly, for treating Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL). The method comprises administering to the subject an effective amount of a CD83 binding protein. The invention also relates to methods for diagnosing and assessing lymphoma in a subject.

traducir

METHODS USING 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE FOR TREATMENT OF INTERMEDIATE LYMPHOCYTIC LYMPHOMA

Nº publicación: US2020276175A1 03/09/2020

Solicitante:

CELGENE CORP [US]

Resumen de: US2020276175A1

Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention. further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention. are also disclosed.

traducir

previousPage Página2 de 3 nextPage por página

punteroimgVolver